Blog
RSS FeedPosted by Michael Wonder on 22 Apr 2020
Wockhardt receives US FDA qualified infectious disease product designation for WCK 6777, a first ever once-a-day β-lactam enhancer class antibiotic
20 April 2020 - WCK 6777 is a once-a-day combination antibiotic based on Wockhardt’s NCE zidebactam, which imparts WCK 6777 ...
Posted by Michael Wonder on 21 Apr 2020
Director of U.S. agency key to vaccine development leaves role suddenly amid coronavirus pandemic
21 April 2020 - Rick Bright, one of the nation’s leading vaccine development experts and the director of the Biomedical ...
Posted by Michael Wonder on 21 Apr 2020
Myovant Sciences Submits new drug application to the FDA for once daily, oral relugolix for the treatment of men with advanced prostate cancer
21 April 2020 - Myovant expects to submit a second application for relugolix combination tablet for women with uterine fibroids in ...
Posted by Michael Wonder on 21 Apr 2020
DOJ clears U.S. drug companies to distribute hydroxychloroquine to coronavirus patients
21 April 2020 - The U.S. Department of Justice on Monday cited "extreme urgency" in clearing U.S. pharmaceutical distributors from ...
Posted by Michael Wonder on 21 Apr 2020
Here’s why a COVID-19 vaccine could end up costing you a small fortune
21 April 2020 - Things have gone from bad to worse for Brian Helstien. For a decade, he’s been grappling ...
Posted by Michael Wonder on 21 Apr 2020
Imbruvica (ibrutinib) receives 11th FDA approval
21 April 2020 - Granted under FDA's real-time oncology review pilot program, Project Orbis and priority review. ...
Posted by Michael Wonder on 21 Apr 2020
Coronavirus puts big pharma’s IP regime to the test
21 April 2020 - “Chaotic” is how Jorge Contreras, a law professor at the University of Utah, describes a struggle ...
Posted by Michael Wonder on 21 Apr 2020
If pharma helps quench the COVID-19 pandemic, what will it want in return?
21 April 2020 - Make no mistake: the only long-term solution to the COVID-19 pandemic is a safe and effective ...
Posted by Michael Wonder on 20 Apr 2020
Hydroxychloroquine and other auto-immune drugs don’t fully protect against coronavirus, early data suggest
18 April 2020 - Data compiled by rheumatology researchers show dozens of patients who were taking Plaquenil and other drugs became ...
Posted by Michael Wonder on 20 Apr 2020
Big pharma has the chance to come to the world’s rescue
20 April 2020 - The pandemic may finally do for the pharmaceutical industry what relentless TV advertising cannot: show off its ...
Posted by Michael Wonder on 20 Apr 2020
FDA and EMA accept applications for Genentech’s Ocrevus (ocrelizumab) shorter two hour infusion time
19 April 2020 - Reduces infusion time to 2 hours from the current 3.5 hours for patients with relapsing or primary ...
Posted by Michael Wonder on 20 Apr 2020
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalised COVID-19 patients
20 April 2020 - Novartis has reached an agreement with the US FDA to proceed with a Phase III clinical trial ...
Posted by Michael Wonder on 18 Apr 2020
NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options
17 April 2020 - The National Institutes of Health (NIH) and the Foundation for the NIH are bringing together more than ...
Posted by Michael Wonder on 18 Apr 2020
Finding effective treatments for COVID-19: scientific integrity and public confidence in a time of crisis
16 April 2020 - Everyone wants new treatments and vaccines to address the devastation of coronavirus disease 2019 (COVID-19). ...
Posted by Michael Wonder on 17 Apr 2020
FDA approves first targeted treatment for patients with cholangiocarcinoma, a cancer of bile ducts
17 April 2020 - Today, the U.S. FDA granted accelerated approval to Pemazyre (pemigatinib), the first treatment approved for adults with ...